Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) ...

Doron Therapeutics, a clinical-stage biotechnology company based in Chapel Hill, has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration ...

Pixee Medical, the world leader in augmented reality navigation technologies for orthopedic surgery, is pleased to announce ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...

Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing technology, a one-time transvaginal ablation procedure designed to restore ovulation in ...

We never sold the combination in the countries where it's banned. Our exports were done only after getting valid product permissions from the State FDA and required export NOCs,' said Arvind Sharma, ...

This is also Sun Pharma's second acquisition in less than three months and comes as the company looks to size up its specialty therapy portfolio.

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

There are always new bike bits, bobs, products, and gear to share. This week in tech news comes all over the spectrum of ...

Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased ...

“I am very pleased with the new FDA approval goal date of June 4, 2025 for our Ketamine drug. We are focused on solving the shortage issue of Ketamine and becoming the leading supplier of Ketamine to ...